Cipla's Strategic Leap into Ophthalmology: A New Licensing Milestone

Cipla has secured exclusive rights to commercialize a novel ophthalmic suspension developed by Formosa Pharmaceuticals. The drug targets post-surgery ocular inflammation. This deal marks Cipla's first multi-regional licensing venture in ophthalmology, expanding its reach to eleven countries, including India and South Africa.

Cipla has taken a strategic leap forward by securing an exclusive licensing agreement with Taiwan's Formosa Pharmaceuticals for the commercialization of clobetasol propionate ophthalmic suspension. This move enables the Mumbai-based pharmaceutical giant to market the innovative treatment targeting post-operative inflammation and pain relief following ocular surgery.

The agreement grants Cipla exclusive marketing rights in eleven nations, including India, South Africa, and Bangladesh. Clobetasol propionate ophthalmic suspension, a novel and patent-protected product, is approved by the USFDA and offers a simple twice-daily dosing regimen for 14 days without tapering. This distinguishes it as a groundbreaking development in the ophthalmic sector, delivering rapid and sustained relief.

Cipla's Global COO, Achin Gupta, celebrated this partnership as a significant milestone, marking the company's first multi-regional licensing agreement in ophthalmology. Meanwhile, Erick Co, President of Formosa Pharmaceuticals, expressed keen anticipation for the collaborative effort to bring novel therapies to patients undergoing ocular surgery.